Recent improvement in long-term survival after a COPD hospitalisation

被引:57
作者
Almagro, Pere [1 ]
Salvado, M. [1 ]
Garcia-Vidal, C. [1 ]
Rodriguez-Carballeira, M. [1 ]
Delgado, M. [1 ]
Barreiro, B. [2 ]
Heredia, J. L. [2 ]
Soriano, Joan B. [3 ]
机构
[1] Univ Hosp Mutua Terrassa, Internal Med Serv, Terrassa, Spain
[2] Univ Hosp Mutua Terrassa, Resp Serv, Terrassa, Spain
[3] Int Ctr Adv Resp Med, Program Epidemiol & Clin Res, Fdn Caubet Cimera Illes Balears, Bunyola, Spain
关键词
OBSTRUCTIVE PULMONARY-DISEASE; FLUTICASONE PROPIONATE; RISK-FACTORS; MORTALITY; EXACERBATIONS; PREVALENCE; TIOTROPIUM; MORBIDITY; SALMETEROL; REDUCTION;
D O I
10.1136/thx.2009.124818
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background Evidence-based international guidelines on chronic obstructive pulmonary disease ( COPD), and their corresponding recommendations, were established to improve individual COPD prognosis, and ultimately to improve survival. The aim of this study was to determine whether the long-term mortality after discharge from a COPD hospitalisation has improved recently, and the effect of co-morbidity treatment in improving COPD prognosis. Methods In a prospective cohort study design of two cohorts 7 years apart, patients discharged from the same university hospital after a COPD exacerbation were followed-up, and their outcomes compared. Demographic and clinical variables, as well as lung function, were collected with the same protocol by the same investigators. Comprehensive assessments of comorbidities and treatments were undertaken. Kaplane-Meier survival curves were estimated, and outcomes were compared by means of Cox regression methods. Results Overall, 135 participants in the 1996-7 cohort and 181 participants in the 2003-4 cohort were studied. Both cohorts were comparable in their baseline demographic and clinical variables, and median follow-up was 439 days. The 3-year mortality was lower in the 2003-4 cohort (38.7%) than in the 1996-7 cohort (47.4%) (p = 0.017), and the RR of death after adjustment for gender, age, body mass index, comorbidities, lung function and mMRC (modified Medical Research Council scale) dyspnoea was 0.66 (95% CI 0.45 to 0.97). Long-term survival improved in the second cohort for patients with COPD with heart failure or cancer (p<0.001). Conclusions A recent trend towards better prognosis of patients with COPD after hospital discharge is described and is likely to be associated with better management and treatment of COPD and co-morbidities.
引用
收藏
页码:298 / 302
页数:5
相关论文
共 35 条
[1]   Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease - A randomized trial [J].
Aaron, Shawn D. ;
Vandemheen, Katherine L. ;
Fergusson, Dean ;
Maltais, Francois ;
Bourbeau, Jean ;
Goldstein, Roger ;
Balter, Meyer ;
O'Donnell, Denis ;
McIvor, Andrew ;
Sharma, Sat ;
Bishop, Graham ;
Anthony, John ;
Cowie, Robert ;
Field, Stephen ;
Hirsch, Andrew ;
Hernandez, Paul ;
Rivington, Robert ;
Road, Jeremy ;
Hoffstein, Victor ;
Hodder, Richard ;
Marciniuk, Darcy ;
McCormack, David ;
Fox, George ;
Cox, Gerard ;
Prins, Henry B. ;
Ford, Gordon ;
Bleskie, Dominique ;
Doucette, Steve ;
Mayers, Irvin ;
Chapman, Kenneth ;
Zamel, Noe ;
FitzGerald, Mark .
ANNALS OF INTERNAL MEDICINE, 2007, 146 (08) :545-U15
[2]   Mortality after hospitalization for COPD [J].
Almagro, P ;
Calbo, E ;
de Echagüen, AO ;
Barreiro, B ;
Quintana, S ;
Heredia, JL ;
Garau, J .
CHEST, 2002, 121 (05) :1441-1448
[3]  
[Anonymous], GLOB STRAT DIAGN MAN
[4]   Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995-99: results of the EUROCARE-4 study [J].
Berrino, Franco ;
De Angelis, Roberta ;
Sant, Milena ;
Rosso, Stefano ;
Lasota, Magdalena B. ;
Coebergh, Jan W. ;
Santaquilani, Mariano .
LANCET ONCOLOGY, 2007, 8 (09) :773-783
[5]   International variation in the prevalence of COPD (The BOLD Study): a population-based prevalence study [J].
Buist, A. Sonia ;
McBurnie, Mary Ann ;
Vollmer, William M. ;
Gillespie, Suzanne ;
Burney, Peter ;
Mannino, David M. ;
Menezes, Ana M. B. ;
Sullivan, Sean D. ;
Lee, Todd A. ;
Weiss, Kevin B. ;
Jensen, Robert L. ;
Marks, Guy B. ;
Gulsvik, Amund ;
Nizankowska-Mogilnicka, Ewa .
LANCET, 2007, 370 (9589) :741-750
[6]   Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial [J].
Burge, PS ;
Calverley, PMA ;
Jones, PW ;
Spencer, S ;
Anderson, JA ;
Maslen, TK .
BMJ-BRITISH MEDICAL JOURNAL, 2000, 320 (7245) :1297-1303
[7]   Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease [J].
Calverley, Peter M. A. ;
Anderson, Julie A. ;
Celli, Bartolome ;
Ferguson, Gary T. ;
Jenkins, Christine ;
Jones, Paul W. ;
Yates, Julie C. ;
Vestbo, Jorgen ;
Calverley, P. M. A. ;
Anderson, J. A. ;
Celli, B. ;
Ferguson, G. T. ;
Jenkins, C. ;
Jones, P. W. ;
Knobil, K. ;
Yates, J. C. ;
Vestbo, J. ;
Cherniack, R. ;
Similowski, T. ;
Cleland, J. ;
Whitehead, A. ;
Wise, R. ;
McGarvey, L. ;
John, M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (08) :775-789
[8]   Mortality in the 4-Year Trial of Tiotropium (UPLIFT) in Patients with Chronic Obstructive Pulmonary Disease [J].
Celli, Bartolome ;
Decramer, Marc ;
Kesten, Steven ;
Liu, Dacheng ;
Mehra, Sunil ;
Tashkin, Donald P. .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2009, 180 (10) :948-955
[9]   Update on the management of COPD [J].
Celli, Bartolome R. .
CHEST, 2008, 133 (06) :1451-1462
[10]   Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper [J].
Celli, BR ;
MacNee, W ;
Agusti, A ;
Anzueto, A ;
Berg, B ;
Buist, AS ;
Calverley, PMA ;
Chavannes, N ;
Dillard, T ;
Fahy, B ;
Fein, A ;
Heffner, J ;
Lareau, S ;
Meek, P ;
Martinez, F ;
McNicholas, W ;
Muris, J ;
Austegard, E ;
Pauwels, R ;
Rennard, S ;
Rossi, A ;
Siafakas, N ;
Tiep, B ;
Vestbo, J ;
Wouters, E ;
ZuWallack, R .
EUROPEAN RESPIRATORY JOURNAL, 2004, 23 (06) :932-946